Table 36.
Mirtazapine for children and adolescents with Anorexia Nervosa
| Certainty assessment | Impact | Certainty | Importance | ||||||
|---|---|---|---|---|---|---|---|---|---|
| № of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | |||
| Weight (assessed with: kg) | |||||||||
| 1 | Case Control | serious a | not serious | not serious | not serious | none | 9 females with AN treated with mirtazapine (mean dose 21.7 mg/day) matched with 9 controls. No significant differences in weight or BMI at the end of 4 weeks of treatment. |
⨁◯◯◯ VERY LOW |
CRITICAL |
| Weight (assessed with: kg) Depression (assessed with: clinical impression) | |||||||||
| 2 | Case Reports | very serious a,b | not serious | not serious | not serious | none | Two case reports (one male, one female) with AN and depression. Both improved in weight. |
⨁◯◯◯ VERY LOW |
CRITICAL |
| very serious a,b | not serious | not serious | not serious | none | One of these case reports mentioned remission of depression in the context of AN with treatment with mirtazapine (30 mg). |
⨁◯◯◯ VERY LOW |
CRITICAL | ||